{
    "Trade/Device Name(s)": [
        "HemosIL\u2122 AcuStar Anti-Cardiolipin IgG",
        "HemosIL\u2122 AcuStar Anti-Cardiolipin IgM",
        "HemosIL\u2122 AcuStar Anti-Cardiolipin IgG Controls",
        "HemosIL\u2122 AcuStar Anti-Cardiolipin IgM Controls"
    ],
    "Submitter Information": "Instrumentation Laboratory Co.",
    "510(k) Number": "K092181",
    "Predicate Device Reference 510(k) Number(s)": [
        "K022992"
    ],
    "Regulatory Class": "Class II (Assays), Class I (Controls)",
    "Product Code(s)": [
        "MID",
        "JJX"
    ],
    "Summary Letter Date": "March 3, 2010",
    "Summary Letter Received Date": "March 8, 2010",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21CFR866.5660",
        "21CFR862.1660"
    ],
    "Regulation Name(s)": [
        "Multiple autoantibodies immunological test system",
        "Single (Specified) Analyte Controls (Assayed and Unassayed)"
    ],
    "Analyte Class(es)": [
        "immunology",
        "autoimmune"
    ],
    "Analyte(s)": [
        "Anti-cardiolipin IgG antibodies",
        "Anti-cardiolipin IgM antibodies"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Citrated Plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "ACL\u2122 AcuStar"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent immunoassay"
    ],
    "Methodologies": [
        "Two-step immunoassay",
        "Semi-quantitative measurement"
    ],
    "Submission Type(s)": [
        "Assay",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for HemosIL AcuStar Anti-Cardiolipin IgG and IgM chemiluminescent immunoassays and controls for detection of anti-cardiolipin antibodies related to Antiphospholipid Syndrome.",
    "Indications for Use Summary": "Automated chemiluminescent immunoassays for the semi-quantitative measurement of anti-cardiolipin IgG and IgM antibodies in human citrated plasma and serum on the ACL AcuStar, as an aid in the diagnosis of thrombotic disorders related to primary and secondary Antiphospholipid Syndrome (APS) when used in conjunction with other laboratory and clinical findings; controls are for quality control of the assays performed on ACL AcuStar.",
    "fda_folder": "Immunology"
}